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study. Further study is warranted for a causal link between general
sickness and speciﬁc cytokines during human GVHD develop-
ment.
Table 1. Correlations between Symptom Severity and IL-8 Levels
before and after the Development of GVHD in the First 100 Days
after Allo-BMT
Symptom Correlation with IL-8 Levels
Pre-GVHD
Shortness of breath r  0.708, P < .01
Dry mouth r  0.667, P < .05
Sadness r  0.631, P < .05
Post-GVHD
Sleep disturbance r  0.564, P < .05
Drowsiness r  0.565, P < .05
Vomiting r  0.558, P < .05
10
INCREASED CLEARANCE OF ASPERGILLUS FUMIGATUS IN MICE WITH
CHRONIC LUNG INJURY AFTER ALLOGENEIC STEM CELL TRANSPLAN-
TATION
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Chronic lung injury (CLI) is a frequent problem after allogeneic
(allo) stem cell transplantation (SCT) leading to obstructive and/or
restrictive changes in lung function. CLI is associated with signif-
icant morbidity and mortality and is frequently complicated by
co-existing opportunistic infections. We developed a murine SCT
model of CLI by transplanting splenocytes and bone marrow cells
from G-CSF treated syngeneic (syn) B6D2F1 or allo C57BL/6
donor mice into lethally irradiated B6D2F1 recipients. Animals
were analyzed between day 90 and 100 after transplant. Allo but
not syn recipients showed typical changes of CLI: pulmonary
resistance was signiﬁcantly increased (146 12 vs. 106 5%), and
lung compliance was decreased (62  6 vs. 77  3%) compared to
syn controls (P  .01) Functional changes correlated with signiﬁ-
cant histopathology, including a dense mononuclear cell inﬁltrate
around bronchial structures (score: 5.3  0.7 vs. 0.3  0.3; P 
.01), peribronchial ﬁbrosis and pulmonary collagen deposition.
Histopathologic changes were associated with increased numbers
of BALF total cells (1.68  0.26 vs. 0.89  0.08  106; P  .01),
and both CD4 (2.9  0.4 vs. 1.4  0.1  105; P  .01) and
CD8 T cells (1.0  0.1 vs. 0.1  0.0  105; P  .01). Interest-
ingly, IFN- CD4 and IFN- CD8 T cells and lung mRNA
for CCR2 were also increased indicating a local proinﬂammatory
environment. Next we determined whether animals with CLI after
allo-SCT were more susceptible to fungal infection than syn con-
trols. SCT recipients were injected intratracheally with 5  106
Aspergillus fumigatus (A.f.) conidia around day 70 and were analyzed
3 weeks later. Surprisingly, recipients of allo-SCT showed in-
creased pulmonary clearance of A.f. with signiﬁcant reductions of
conidia within the bronchial epithelium and of associated goblet
cell hyperplasia compared to syn controls. Conclusion: Despite
the development of signiﬁcant CLI, allo-SCT recipients have en-
hanced clearance of A.f. conidia compared to syn controls. These
data suggest that the proinﬂammatory micro-environment associ-
ated with non-infectious lung injury after SCT may have a here-
tofore unidentiﬁed beneﬁcial effect on immune surveillance, per-
haps calling into question the merits of continuing systemic
immunosuppression in patients with CLI without evidence for
clear improvements in lung function.
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DONOR-SPECIFIC CELL ENGRAFTMENT AFTER INTRAOSSEOUS AND
INTRAVENOUS BONE MARROW TRANSPLANTATION
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Background: Engraftment of donor-derived bone marrow cells
into recipient bone marrow environment can induce hematopoietic
chimerism and tolerance to antigen-matched organs in solid organ
and composite tissue allograft. This study was designed to inves-
tigate the effect of intraosseous bone marrow transplantation
(BMT) for donor cells engraftment into the bone marrow envi-
ronment and lymphoid tissue compartment across MHC barrier
under short-term 
-TCRmAb/CsA protocols. Materials and
Methods: Forty-eight BMT were performed between ACI (RT1a)
donors and LEW (RT1l) recipients. Intraosseous and intravenous
BMT was studied in 6 groups of 8 animals each receiving 35  106
(n  4) and 70  106 (n  4) bone marrow cells. Groups I and II
(controls) received BMT but no treatment, groups III and IV CsA
monotherapy, and groups V, VI 
-TCRmAb/CsA protocol for 7
days. Flow cytometry monitored immunodepletion and donor-
speciﬁc chimerism for MHC class I (RT1a) antigens in the periph-
eral blood and bone marrow compartment. Immunocytochemical
staining was employed to detect the presence of donor-derived
cells in the lymphoid tissue of recipients. Results: All animals
survived without the occurrence of graft versus host disease. Short
term 
-TCRmAb/CsA protocol and 70  106 bone marrow cells
delivery resulted in 7.9%  1.3% of donor cell engraftment after
intraosseous BMT compared to 4.2%  1.4% after intravenous
transplantation. Donor bone marrow cell engraftment into the
recipient bone marrow compartment delivered via the intraosseous
route under the 
-TCRmAb/CsA protocol was 40% more efﬁ-
cient after 70  106 bone marrow cell transplantation compared to
35  106 (7.9% vs 4.8% respectively). Also, CsA monotherapy and
70  106 bone marrow cell delivery resulted in better engraftment
of donor cells after intraosseous transplantation compared to 35 
106 of BMT (3.8% vs 2.2% respectively). Donor-derived cells were
present in the lymph nodes and spleen of recipients. Higher seed-
ing efﬁciency of donor cells into the lymphoid tissue compartment
was achieved after intraosseous BMT and 
-TCRmAb/CsA pro-
tocol compared to standard intravenous transplantation. Conclu-
sion: Intraosseous transplantation of donor bone marrow cells
under 
-TCRmAb/CsA protocol was more effective for donor
cell engraftment into recipients’ bone marrow environment and
lymphoid tissue compartment compared to intravenous transplan-
tation.
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Results of the EORTC ALL-3 reveal that the policy to perform
allo-SCT in a case when a sibling donor is available does not result
in a signiﬁcantly better outcome than to offer auto-SCT or con-
tinuous maintenance. We also analysed the outcome of allografted
patients in EORTC ALL-4. In this trial patients were randomized
to receive either dexamethasone (10 mg/m2/day) or 6-methyl-
prednisolone (60 mg/m2/day) on days 1-8 and 15-22 with standard
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